Pharmacokinetic interactions
Effect of other medicinal products on CAMZYOS
In CYP2C19 intermediate, normal, rapid and ultra-rapid metabolisers, CAMZYOS is primarily metabolised by CYP2C19 and to a lesser extent by CYP3A4. In CYP2C19 poor metabolisers, metabolism is mostly by CYP3A4. CYP2C19 inhibitors/inducers and CYP3A4 inhibitors/inducers may thus affect the clearance of CAMZYOS and increase/decrease CAMZYOS plasma concentration, and this will depend on the CYP2C19 phenotype.
All clinical drug-drug interaction studies mainly enrolled CYP2C19 normal metabolisers and no CYP2C19 poor metabolisers were included in the assessment of the drug-drug interaction and therefore the effect of co-administration of CYP2C19 and CYP3A4 inhibitors with CAMZYOS in CYP2C19 poor metabolisers is not completely certain.